Obesity prevalence in the US decreased in 2023, with significant drops in the South, highlighting the impact of GLP-1RA medications on health trends.
Obesity prevalence in the US decreased in 2023, with significant drops in the South, highlighting the impact of GLP-1RA medications on health trends.